Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BMO Capital Reiterates Market Perform on CytomX Therapeutics, Maintains $3.25 Price Target

Author: Benzinga Newsdesk | May 01, 2024 12:11pm

BMO Capital analyst Etzer Darout reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and maintains $3.25 price target.

Posted In: CTMX